

Express Mail No. EV669614044US
Date of Deposit: June 2, 2006
PATENT

SLR:dm 06/01/06 5585-75901-01 533171 RCD/P104199

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Bernard Corfe and Hari Chirakkal

Application No. Currently unknown

Filed: Herewith

Confirmation No. Currently unknown

For: GENE SCREEN

Examiner: Not yet assigned

Art Unit: Not yet assigned

Attorney Reference No. 5585-75901-01

MAIL STOP PCT
COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97(b)(2)

Listed on the accompanying form PTO-1449 and enclosed herewith are several English-language documents and one non-English-language document. The relevance of the non-English language document can be ascertained from the English-language abstract attached to the document. Applicants respectfully request that these documents be listed as references cited on the issued patent.

Copies of United States patents and United States published patent applications do not have to be provided to the Patent Office (37 C.F.R. 1.98(a)(2)(ii)). Copies of unpublished U.S. applications do not have to be provided, as long as the application is available on PAIR, as this requirement of 37 C.F.R. § 1.98(a)(2)(iii) has been waived by the United States Patent and Trademark Office pursuant to the Official Gazette Notice on October 19, 2004 (1287 OG 163). Applicants will provide copies of such patents or applications upon request.

Applicants filed this Information Disclosure Statement ("IDS") within three months of the date of entry of the national stage as set forth in § 1.491 in an international application. As a

10/581702

Express Mail No. EV669614044US

Date of Deposit: June 2, 2006

PATENT

SLR:dm 06/01/06 5585-75901-01 533171 RCD/P104199


AP20 Rec'd PCT/PTO 02 JUN 2006

result, no fee should be required to file this IDS. However, if the Patent Office determines that a fee is required for Applicants to file this IDS, please charge any such fees, or credit overpayment, to Deposit Account No. 02-4550. A **duplicate** copy of this IDS is enclosed.

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By 
Sheree Lynn Rybak, Ph.D.
Registration No. 47,913

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 226-7391
Facsimile: (503) 228-9446

cc: Docketing

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Attorney Docket Number	5585-75901-01
Application Number	Currently unknown
Filing Date	June 2, 2006
First Named Inventor	Corfe
Art Unit	Not yet assigned
Examiner Name	Not yet assigned

U.S. PATENT DOCUMENTS

Copies of U.S. Patent documents do not need to be provided, unless requested by the Patent and Trademark Office. For patents, provide the patent number and the issue date. For published U.S. applications, provide the publication number and the publication date. For unpublished pending patent applications, provide the application number and the filing date.

Examiner's Initials*	Cite No. (optional)	Number	Publication Date	Name of Applicant or Patentee
		US 2003/0099974 A1	05/29/2003	Lillie et al.

FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Country	Number	Publication Date	Name of Applicant or Patentee
		EPC	EP 0 836 096 A2	04/15/1998	Smithkline Beecham Corporation and Smithkline Beecham PLC
		WIPO	WO 01/85944 A2	11/15/2001	Mitokor
		WIPO	WO 03/058021 A2	07/17/2003	Xantos Biomedicine AG

Examiner's Initials*	Cite No. (optional)	OTHER DOCUMENTS
		Iacomino et al., "Transcriptional Response of a Human Colon Adenocarcinoma Cell Line to Sodium Butyrate," <i>Biochem. Biophys. Res. Commun.</i> 285:1280-1289 (2001).

EXAMINER SIGNATURE:	DATE CONSIDERED:
---------------------	------------------

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.